ADA–SCID This is a partner's product, where Oxford Biomedica provide process development and bioprocessing. For more information on Orchard Therapeutics products their website. Autologous ex-vivo lentiviral gene therapy Orchard is developing ex-vivo lentiviral gene therapy to restore normal gene function in patients with ADA-SCID Summary of clinical data to date* >30 patients treated at UCL and UCLA as of March 2016 100% survival with a follow-up of 2–49 months Evidence of immune reconstitution No evidence of insertional mutagenesis For more information please contact: info@orchard-tx.com http://orchard-tx.com/programmes/#ada-scid Good luck and GOD bless, George